Diabetes Tipe Lainnya (MODY, LADA, dll)

01Pathophysiology

MODY (Maturity-Onset Diabetes of the Young)

MODY is caused by a single gene mutation inherited in an autosomal dominant pattern that directly impairs beta-cell function. Unlike Type 2 diabetes, insulin resistance is not the primary mechanism. The defect lies within the beta cell itself, either in its glucose-sensing apparatus or in transcription factors that regulate insulin gene expression and beta-cell development.

The most clinically important distinction among MODY subtypes is between those that cause a resettable glucose thermostat (MODY 2/GCK) versus those that cause progressive beta-cell failure (MODY 1, 3, and 5).

In MODY 2 (glucokinase mutation), glucokinase serves as the beta cell's "glucose sensor." It catalyzes the rate-limiting step of glucose phosphorylation and thereby determines the threshold at which insulin secretion is triggered. A heterozygous loss-of-function mutation shifts this set point upward. The beta cell still responds to glucose normally; it simply requires a higher glucose level to begin secreting insulin. This is why the hyperglycemia is mild, stable, and non-progressive. The body reaches a new equilibrium and stays there.

In MODY 3 (HNF1-alpha mutation), HNF1-alpha is a transcription factor essential for maintaining beta-cell mass and regulating the insulin gene. Loss of function causes progressive decline in insulin secretion over years. A distinctive feature is a low renal threshold for glucose reabsorption, meaning these patients develop glycosuria at blood glucose levels that would not cause glycosuria in other forms of diabetes. This occurs because HNF1-alpha is also expressed in the renal proximal tubule and regulates SGLT2 transporter expression.

In MODY 1 (HNF4-alpha mutation), the mechanism is similar to MODY 3 because HNF4-alpha is upstream of HNF1-alpha in the transcription factor cascade. The disease is progressive and sulfonylurea-responsive. A unique feature is that HNF4-alpha also regulates fetal insulin secretion. Affected neonates may present with transient neonatal macrosomia and hyperinsulinemic hypoglycemia before later developing diabetes.

In MODY 5 (HNF1-beta mutation), this transcription factor plays roles in the development of the kidneys, pancreas, and genital tract. Mutations lead to the Renal Cysts and Diabetes (RCAD) syndrome. Pancreatic hypoplasia explains both the exocrine insufficiency and the diabetes, which tends to be more severe and insulin-requiring.

LADA (Latent Autoimmune Diabetes in Adults)

LADA shares the same fundamental pathogenesis as Type 1 diabetes: autoimmune destruction of pancreatic beta cells mediated by T-lymphocytes, with detectable circulating autoantibodies. The key difference is the rate of destruction. In classic Type 1 DM, the autoimmune attack is rapid and aggressive, leading to absolute insulin deficiency within weeks to months. In LADA, the process is indolent, taking months to years before the patient becomes insulin-dependent.

At diagnosis, these patients still have sufficient residual beta-cell mass to maintain adequate insulin production. This is why they initially look like Type 2 patients and can be managed without insulin. However, the autoimmune process continues relentlessly in the background, and C-peptide levels decline progressively until the patient reaches absolute insulin deficiency.

LADA shares genetic susceptibility loci with Type 1 DM (particularly HLA-DR3 and HLA-DR4), but the autoimmune response is less aggressive, possibly due to a different balance of effector and regulatory T-cell activity.

Neonatal Diabetes Mellitus (NDM)

Diabetes diagnosed before 6 months of age is almost never autoimmune Type 1 DM. It is virtually always monogenic. The most important cause involves activating mutations in the genes encoding subunits of the KATP channel (KCNJ11 encoding Kir6.2, and ABCC8 encoding SUR1).

Under normal physiology, glucose enters the beta cell, is metabolized to produce ATP, and the rising ATP:ADP ratio causes KATP channels to close. Channel closure leads to membrane depolarization, calcium influx, and insulin exocytosis. An activating (gain-of-function) mutation keeps these channels constitutively open, preventing depolarization regardless of the intracellular glucose or ATP level. The result is a complete block of glucose-stimulated insulin secretion.

This mechanism is directly targetable: sulfonylureas bind to the SUR1 subunit and force channel closure independently of ATP, thereby restoring insulin secretion. This is why identifying the genetic cause in neonatal diabetes is not merely academic but profoundly therapeutic.

Some KCNJ11 mutations also affect KATP channels in the brain and skeletal muscle, producing DEND syndrome (Developmental delay, Epilepsy, Neonatal Diabetes). An intermediate form (iDEND) has milder neurological features.

Transient neonatal diabetes (TNDM) is most commonly caused by imprinting abnormalities on chromosome 6q24. It resolves in infancy but may recur as diabetes later in life, often during puberty or pregnancy.

Type 3c (Pancreatogenic Diabetes)

When exocrine pancreatic tissue is destroyed, the closely interspersed islets of Langerhans are destroyed along with it. This leads to loss of not just beta cells (insulin) but also alpha cells (glucagon) and PP cells (pancreatic polypeptide). The combination of insulin deficiency and glucagon deficiency creates a uniquely brittle form of diabetes. Without glucagon, the counter-regulatory response to hypoglycemia is severely impaired, making these patients prone to both hyperglycemia and severe, unpredictable hypoglycemia.

Additionally, exocrine insufficiency causes malabsorption of fats and fat-soluble vitamins (A, D, E, K), further complicating metabolic management. Nutrient delivery to the gut becomes erratic, making carbohydrate absorption unpredictable and insulin dosing difficult.

The most common cause is chronic pancreatitis (especially alcohol-related), followed by pancreatic cancer, cystic fibrosis, and hemochromatosis. Post-surgical diabetes after partial or total pancreatectomy follows the same pathophysiology.

Drug-Induced Diabetes

The mechanism varies by drug class. Glucocorticoids increase hepatic gluconeogenesis, promote peripheral insulin resistance by antagonizing insulin signaling at the post-receptor level, and directly suppress beta-cell insulin secretion. The hyperglycemia is characteristically worse in the afternoon and evening, reflecting the pharmacokinetics of morning-dosed steroids.

Calcineurin inhibitors (tacrolimus more than cyclosporine) cause direct beta-cell toxicity by interfering with calcineurin-NFAT signaling, which is required for insulin gene transcription. Tacrolimus is the single most important cause of new-onset diabetes after transplantation (NODAT).

Atypical antipsychotics (olanzapine and clozapine being the worst offenders) cause both weight gain through appetite stimulation and direct impairment of insulin signaling independent of weight gain.

Endocrinopathy-Associated Diabetes

Each endocrinopathy causes diabetes through hormone-excess pathways:

• Cushing syndrome: cortisol excess drives gluconeogenesis and insulin resistance

• Acromegaly: growth hormone excess promotes hepatic glucose output and peripheral insulin resistance

• Pheochromocytoma: catecholamine excess stimulates glycogenolysis and gluconeogenesis while directly inhibiting insulin secretion via alpha-2 adrenergic receptors on beta cells

• Glucagonoma: glucagon excess drives unrestrained hepatic glucose production; classically associated with the triad of diabetes + weight loss + necrolytic migratory erythema

• Somatostatinoma: somatostatin inhibits both insulin and glucagon secretion; associated with the triad of diabetes + gallstones + steatorrhea

02Classification and Clinical Manifestation

MODY Subtypes

LADA Diagnostic Criteria

Neonatal Diabetes Classification

Secondary Causes of Diabetes

Wolfram Syndrome (DIDMOAD)

This genetic syndrome deserves separate mention because it is a classic exam entity:

03Diagnostic Workup

When to Suspect MODY

The classical clinical clue is a young patient (under 25-35) with diabetes who is not obese, has a strong family history of diabetes across at least 2-3 generations in an autosomal dominant pattern, and tests negative for all islet autoantibodies. This triad should immediately trigger consideration of MODY.

The initial workup should include fasting glucose and HbA1c to quantify the degree of hyperglycemia, followed by an autoantibody panel (anti-GAD65, anti-IA2, anti-ZnT8, ICA), all of which should be negative in MODY. Fasting C-peptide should be preserved or normal (>0.6 ng/mL), indicating ongoing beta-cell function. This distinguishes MODY from Type 1 DM, where C-peptide is low or undetectable. Urinalysis may show glycosuria at relatively low blood glucose in MODY 3 (HNF1-alpha).

If clinical suspicion remains high after these tests are consistent with MODY, the confirmatory step is targeted genetic testing. In many centers, a MODY gene panel covering at least GCK, HNF1A, HNF4A, and HNF1B is the standard approach.

A useful clinical heuristic: if a patient diagnosed with "Type 1" still has detectable C-peptide more than 3-5 years after diagnosis, MODY should be reconsidered.

Diagnosing LADA

LADA should be suspected in any adult patient initially diagnosed with Type 2 DM who is lean, has no features of metabolic syndrome, and shows unexpectedly rapid failure of oral hypoglycemic agents.

The critical test is the anti-GAD65 antibody. This is the single most sensitive and persistent autoantibody in LADA. Anti-IA2 and anti-ZnT8 may also be positive but tend to decline earlier.

C-peptide levels should be measured at diagnosis and monitored longitudinally. At diagnosis, C-peptide is typically in the low-normal range (higher than classic Type 1 but lower than Type 2). Over time, C-peptide declines progressively, reflecting ongoing autoimmune beta-cell destruction.

The practical distinction from Type 2 DM: a patient diagnosed as Type 2 who becomes insulin-dependent within 3-5 years and has positive autoantibodies almost certainly has LADA.

Neonatal Diabetes

Any infant presenting with diabetes before 6 months of age should undergo genetic testing rather than being assumed to have Type 1 DM. The rationale is that autoimmune Type 1 DM is exceedingly rare before 6 months because the autoimmune process requires time to develop. Autoantibody testing is typically negative. Genetic testing should target KCNJ11, ABCC8, INS gene, and 6q24 methylation analysis as first-line.

Type 3c (Pancreatogenic Diabetes)

The clue is diabetes developing in the setting of known pancreatic disease. The workup includes fecal elastase-1 (<200 mcg/g confirms exocrine pancreatic insufficiency; <100 mcg/g indicates severe insufficiency), cross-sectional imaging (CT or MRCP) to identify calcifications, atrophy, ductal changes, cysts, or masses, and fat-soluble vitamin levels (A, D, E, K), which are frequently deficient.

04Management and Treatment

MODY

MODY 2 (GCK): Treatment is not needed in the majority of cases. The hyperglycemia is mild and stable, and the rate of microvascular complications is not significantly elevated at the glucose levels typically seen. During pregnancy, however, the situation changes: if the fetus has inherited the GCK mutation, the fetal glucose set point is also raised and insulin treatment of the mother is unnecessary (and may cause fetal growth restriction). If the fetus has a normal genotype, maternal hyperglycemia will drive fetal macrosomia and insulin should be used. Fetal growth monitoring by ultrasound guides this decision when fetal genotype is unknown.

MODY 1 and MODY 3: Low-dose sulfonylureas are the treatment of choice. These patients are remarkably sensitive to sulfonylureas because the beta-cell machinery downstream of the receptor is intact; it is the transcription factor input that is impaired. For MODY 3, starting doses should be approximately one-quarter of the standard Type 2 DM dose (e.g., gliclazide 20-40 mg/day rather than 80-160 mg). Hypoglycemia is a real risk if standard doses are used. As the disease progresses over years, some patients will eventually require insulin.

MODY 5: Typically requires insulin from the outset because pancreatic hypoplasia limits beta-cell mass. These patients also need monitoring and treatment of renal anomalies and may require pancreatic enzyme replacement if exocrine function is impaired.

LADA

The guiding principle is beta-cell preservation. Early initiation of insulin, even at low doses, is recommended to rest the beta cells and potentially slow autoimmune destruction. Many experts advocate for basal insulin introduction soon after diagnosis rather than waiting for oral agent failure.

Metformin may be used as adjunctive therapy for its insulin-sensitizing effects but should not be relied upon as monotherapy. Sulfonylureas should be avoided in LADA. While they may transiently improve glycemic control, they force the already-stressed beta cells to increase insulin output, potentially accelerating their destruction. This is a common exam trap.

DPP-4 inhibitors and GLP-1 receptor agonists are of theoretical interest because of potential beta-cell protective effects, but evidence is still evolving and they are not standard first-line for LADA. As C-peptide declines, the patient should be transitioned to a basal-bolus insulin regimen identical to that used in Type 1 DM.

Neonatal Diabetes with KATP Channel Mutations

This represents one of the most dramatic examples of pharmacogenomics in clinical medicine. Patients with activating mutations in KCNJ11 or ABCC8 can often be successfully switched from insulin injections to oral sulfonylureas. The protocol involves confirming the KATP channel mutation by genetic testing, initiating glibenclamide (glyburide) at 0.1 mg/kg/day while maintaining insulin, gradually increasing the sulfonylurea dose (up to 0.5-1 mg/kg/day, sometimes higher) while weaning insulin, and monitoring blood glucose closely during the transition.

The success rate for insulin-to-sulfonylurea transfer in KCNJ11 mutations is approximately 90%. Beyond glycemic control, sulfonylureas may also improve neurological outcomes in patients with DEND or iDEND syndrome because they act on KATP channels in the brain.

Type 3c (Pancreatogenic Diabetes)

Management requires addressing both endocrine and exocrine components. Insulin therapy is usually required. These patients tend to have brittle diabetes with wide glycemic swings because of concurrent glucagon deficiency. Basal-bolus insulin regimens are preferred but must be titrated carefully due to hypoglycemia risk. Pancreatic enzyme replacement therapy (PERT) with lipase-containing preparations (e.g., pancrelipase 25,000-75,000 units of lipase per meal) is essential for managing malabsorption and for making carbohydrate absorption more predictable, which indirectly improves glycemic control. Fat-soluble vitamin supplementation (A, D, E, K) should be provided with routine monitoring. Metformin should be avoided if significant malnutrition or malabsorption is present. Sulfonylureas are generally avoided due to unpredictable beta-cell reserve.

Drug-Induced Diabetes

The primary management step is to discontinue or reduce the dose of the offending agent when medically feasible.

For steroid-induced diabetes, a useful pharmacokinetic-pharmacodynamic matching strategy: morning prednisone causes predominantly afternoon and evening hyperglycemia. NPH insulin given in the morning (starting at 0.1-0.3 units/kg) provides peak action that coincides with the steroid effect. Basal-bolus insulin or premixed insulin may be needed for patients on higher steroid doses.

For post-transplant diabetes caused by tacrolimus, consider switching to cyclosporine (lower diabetogenic potential) if feasible. If the switch is not possible, manage with insulin.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get questions about "other types of diabetes" wrong is by defaulting to Type 1 or Type 2 without recognizing atypical features in the vignette. The examiners test whether you can identify the red flags that should make you question a straightforward Type 1 or Type 2 diagnosis.

Trap 1: Misdiagnosing MODY as Type 1 in a young patient. A young patient on insulin does not automatically have Type 1 DM. If the vignette emphasizes a strong autosomal dominant family history, absence of autoantibodies, and preserved C-peptide years after diagnosis, the answer is MODY, not Type 1. The "next best step" is genetic testing, and the clinical impact is that the patient may be able to switch from insulin to sulfonylureas.

Trap 2: Treating MODY 2 (GCK) with medications. If a vignette describes a young, non-obese patient with mild, stable fasting hyperglycemia (HbA1c around 6-7%), negative autoantibodies, and a strong family history, and asks for the best management, the answer is no pharmacologic treatment. Students who pick metformin or a sulfonylurea are falling for the impulse to treat every elevated glucose.

Trap 3: Using sulfonylureas in LADA. A lean adult "Type 2" patient who fails oral agents quickly should trigger suspicion for LADA. Check GAD65 antibodies. If positive, the correct management is early insulin, not a sulfonylurea. Sulfonylureas may cause transient improvement but accelerate beta-cell destruction.

Trap 4: Not switching neonatal diabetes to sulfonylurea. If a vignette presents an infant with diabetes diagnosed before 6 months of age and a confirmed KATP channel mutation, the expected answer is that the child should be transitioned from insulin to oral sulfonylurea. This is one of the few situations in medicine where a patient on insulin should be switched to an oral agent.

Trap 5: Ignoring exocrine insufficiency in Type 3c. If a patient with chronic pancreatitis develops diabetes, the management must include both insulin AND pancreatic enzyme replacement. Students who only address the hyperglycemia and forget the malabsorption will miss the complete answer. The brittle glucose control with unpredictable hypoglycemia should clue you in to glucagon deficiency.

Trap 6: Forgetting endocrinopathy-associated diabetes. When a vignette describes new-onset diabetes alongside classic features of Cushing syndrome, acromegaly, or pheochromocytoma, the "next best step" is to address the underlying endocrinopathy, not to start diabetes medications. Treating the hormone excess often resolves or significantly improves the diabetes.

Core competencies being tested: Pattern recognition of atypical features distinguishing "other" diabetes types from Type 1 and Type 2. Precision in management, knowing that MODY 2 requires nothing, MODY 3 requires low-dose sulfonylurea, LADA requires early insulin, and neonatal KATP mutations require sulfonylurea transfer. Appreciation that genetic diagnosis directly changes treatment in MODY and neonatal diabetes. Understanding that Type 3c requires treatment of both endocrine and exocrine components simultaneously.